Cristina Arias / Cover / Getty Images
Johnson & Johnson (JNJ) on Tuesday reported better-than-expected first-quarter results and lifted its sales forecast for the full year.
The pharmaceutical and Medical Technology firm posted adjusted earnings (EPS) of 2.77 on revenue $21.89 billion. Visible Alpha estimates had analysts expecting $2.56 billion and $21.89 billion respectively.
Johnson & Johnson shares were down about 0.6% shortly after the market opened. They were up 7% at the start of the day.
The company increased its projected operating sales range from $89.2 billion up to $90.0 billion. It also held its adjusted EPS forecast steady at $10.50 to $10.70, "including tariff costs, dilution from the Intra-Cellular Therapies acquisition, and updated foreign exchange."
CFO Says J&J Expects $400M in 2025 Tariff Costs
CFO Joseph Wolk said on CNBC following the report’s release that Johnson & Johnson expects tariff costs of roughly $400 million this year. The company announced that its quarterly dividend will be increased to $1.30 from $1.24, marking 63 years of dividend increases.
Since announcing a disappointing 2025 outlook in January, the Company closed its nearly 15 billion dollar acquisition of Intra-Cellular Therapies. It also announced plans to raise its U.S. Investment to more than 55 billion dollars over the next four year.
Johnson & Johnson stock slipped earlier this month after a judge rejected its proposed “prepackaged bankruptcy plan” for a subsidiary that would settle thousands of claims alleging its talc products caused cancer.
UPDATE—This article has been updated with the latest share price information, along with details from CFO Joseph Wolk's CNBC appearance and the company's new dividend.
